GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Cyclically Adjusted PS Ratio

Astellas Pharma (STU:YPH) Cyclically Adjusted PS Ratio : 2.11 (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Astellas Pharma Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Astellas Pharma's current share price is €9.326. Astellas Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €4.43. Astellas Pharma's Cyclically Adjusted PS Ratio for today is 2.11.

The historical rank and industry rank for Astellas Pharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:YPH' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.01   Med: 2.98   Max: 3.8
Current: 2.1

During the past years, Astellas Pharma's highest Cyclically Adjusted PS Ratio was 3.80. The lowest was 2.01. And the median was 2.98.

STU:YPH's Cyclically Adjusted PS Ratio is ranked worse than
50.81% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs STU:YPH: 2.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Astellas Pharma's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.414. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €4.43 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Astellas Pharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted PS Ratio Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 2.85 3.03 2.74 2.23

Astellas Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 3.07 2.90 2.32 2.23

Competitive Comparison of Astellas Pharma's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PS Ratio falls into.



Astellas Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Astellas Pharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=9.326/4.43
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Astellas Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.414/107.2000*107.2000
=1.414

Current CPI (Mar. 2024) = 107.2000.

Astellas Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.957 98.000 1.047
201409 0.978 98.500 1.064
201412 1.101 97.900 1.206
201503 1.026 97.900 1.123
201506 1.129 98.400 1.230
201509 1.177 98.500 1.281
201512 1.326 98.100 1.449
201603 1.144 97.900 1.253
201606 1.341 98.100 1.465
201609 1.292 98.000 1.413
201612 1.371 98.400 1.494
201703 1.217 98.100 1.330
201706 1.252 98.500 1.363
201709 1.174 98.800 1.274
201712 1.333 99.400 1.438
201803 1.152 99.200 1.245
201806 1.297 99.200 1.402
201809 1.256 99.900 1.348
201812 1.458 99.700 1.568
201903 1.261 99.700 1.356
201906 1.450 99.800 1.558
201909 1.415 100.100 1.515
201912 1.486 100.500 1.585
202003 1.412 100.300 1.509
202006 1.363 99.900 1.463
202009 1.335 99.900 1.433
202012 1.387 99.300 1.497
202103 1.284 99.900 1.378
202106 1.326 99.500 1.429
202109 1.355 100.100 1.451
202112 1.429 100.100 1.530
202203 1.264 101.100 1.340
202206 1.477 101.800 1.555
202209 1.471 103.100 1.529
202212 1.544 104.100 1.590
202303 1.355 104.400 1.391
202306 1.361 105.200 1.387
202309 1.380 106.200 1.393
202312 1.492 106.800 1.498
202403 1.414 107.200 1.414

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Astellas Pharma  (STU:YPH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Astellas Pharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (STU:YPH) Business Description

Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (STU:YPH) Headlines

No Headlines